---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023570"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:47.869335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M

## Summary
- XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.
- Raised $8.8M gross proceeds in H1 2025; cash $6.5M at June 30, expected to fund operations into Q2 2026.
- R&D expenses $0.6M in Q2 2025 vs $2.0M in Q2 2024, decrease due to STAR-1 completion.
- G&A expenses $1.2M in Q2 2025 vs $0.9M in Q2 2024; increase from compliance and personnel costs.

## SEC filing metadata
- accession: 0001641172-25-023570
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/0001641172-25-023570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023570
- JSON: https://secwatch.observer/filing/0001641172-25-023570.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.